Further evidence for a role of S100B in mood disorders: A human gene expression mega-analysis

Journal of Psychiatric Research

Volumn 53, Issue 1, 2014, Pages 84-86

  Schroeter, Matthias L ^a,b   Steiner, Johann ^c   Schönknecht, Peter ^b   Mueller, Karsten ^a  

^a MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Depression; Glia; Mania; Mood disorder; S100B

Indexed keywords

MOOD STABILIZER; PROTEIN S100B;

AMYGDALOID NUCLEUS; ASTROCYTE; BRAIN REGION; CELL DENSITY; CELL DIFFERENTIATION; FRONTAL CORTEX; GENE EXPRESSION; GLIA CELL; HIPPOCAMPAL CA1 REGION; HUMAN; LETTER; MAJOR DEPRESSION; MOOD DISORDER; NONHUMAN; OLIGODENDROGLIA; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN CONTENT; BRAIN; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BRAIN; GENE EXPRESSION; HUMANS; MOOD DISORDERS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT;

EID: 84897378560     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.02.021     Document Type: Letter

References (20)

1. Akhisaroglu M., Manev R., Akhisaroglu E., Uz T., Manev H. Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 2003, 14:1471-1473.
2. Dean B., Gray L., Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Australian & New Zealand Journal of Psychiatry 2006, 40:217-224.
3. Femenia T., Gomez-Galan M., Lindskog M., Magara S. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Research 2012, 1476:58-70.
4. Gos T., Schroeter M.L., Lessel W., Bernstein H.G., Dobrowolny H., Schiltz K., et al. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. Journal of Psychiatric Research 2013, 47:1694-1699.
5. Huang C.T., Chen C.H. Identification of gene transcripts in rat frontal cortex that are regulated by repeated electroconvulsive seizure treatment. Neuropsychobiology 2008, 58:171-177.
6. Jurata L.W., Bukhman Y.V., Charles V., Capriglione F., Bullard J., Lemire A.L., et al. Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. Journal of Neuroscience Methods 2004, 138:173-188.
7. Luo K.R., Hong C.J., Liou Y.J., Hou S.J., Huang Y.H., Tsai S.J. Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:1433-1439.
8. Pirooznia M., Seifuddin F., Judy J., Goes F.S., Potash J.B., Zandi P.P. Metamoodics: meta-analysis and bioinformatics resource for mood disorders. Molecular Psychiatry 2013, published online. 10.1038/mp.2013.118.
9. Rajkowska G. Dysfunction of neural circuits involved in the pathophysiology of mood disorders: postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biological Psychiatry 2000, 48:766-777.
10. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS & Neurological Disorders - Drug Targets 2007, 6:219-233.
11. Rong H., Wang G., Liu T., Wang H., Wan Q., Weng S. Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor. International Journal of Molecular Sciences 2010, 11:5310-5322.
12. Ryan M.M., Lockstone H.E., Huffaker S.J., Wayland M.T., Webster M.J., Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Molecular Psychiatry 2006, 11:965-978.
13. Sacher J., Neumann J., Fünfstück T., Soliman A., Villringer A., Schroeter M.L. Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. Journal of Affective Disorders 2012, 140:142-148.
14. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Molecular Psychiatry 2009, 14:235-237.
15. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. Serum markers support disease-specific glial pathology in major depression. Journal of Affective Disorders 2008, 111:271-280.
16. Schroeter M.L., Steiner J., Mueller K. Glial pathology is modified by age in mood disorders - a systematic meta-analysis of serum S100B invivo studies. Journal of Affective Disorders 2011, 134:32-38.
17. Schroeter M.L., Sacher J., Steiner J., Schoenknecht P., Mueller K. Serum S100B represents a new biomarker for mood disorders. Current Drug Targets 2013, 14:1237-1248.
18. Seifuddin F., Pirooznia M., Judy J.T., Goes F.S., Potash J.B., Zandi P.P. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry 2013, 13:213.
19. Small S.A., Schobel S.A., Buxton R.B., Witter M.P., Barnes C.A. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nature Reviews Neuroscience 2011, 12:585-601.
20. Ye Y., Wang G., Wang H., Wang X. Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neuroscience Letters 2011, 503:15-19.